Who Paid My Doc
Kristy King
Registered Nurse, General Practice Linden, TN Nurse Practitioner
NPI 1841278546 CMS profile 10752195
115 E Brooklyn Ave, Linden, TN 37096
General payments
$13
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Kristy King of Linden, TN is reported in the CMS Open Payments database as having received $13 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 1st percentile of Registered Nurse, General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $13 | 1 |
Beside peers
- Kristy King
- Registered Nurse, General Practice median
- Middle half of Registered Nurse, General Practice
- National median
In program year 2025, general payments to Kristy King were reported at $0. Among 146 Registered Nurse, General Practice profiles paid that year, the median was $117 and the middle half received between $27 and $348.
Show as a table
| Year | Kristy King | Registered Nurse, General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $13 | $92 | $30–$313 | $132 |
| 2022 | $0 | $85 | $28–$243 | $149 |
| 2023 | $0 | $121 | $51–$290 | $160 |
| 2024 | $0 | $127 | $42–$316 | $164 |
| 2025 | $0 | $117 | $27–$348 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 136 drugsPart D claims
7,100
Drug cost
$327,717
Branded share of claims
19.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 59 | $43,410 | |
| Ozempic Semaglutide | Brand | 33 | $36,057 | |
| Farxiga Dapagliflozin Propanediol | Brand | 22 | $31,036 | |
| Jardiance Empagliflozin | Brand | 18 | $20,695 | |
| Xarelto Rivaroxaban | Brand | 13 | $20,562 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 22 | $19,262 | |
| Trulicity Dulaglutide | Brand | 13 | $17,722 | |
| Mounjaro Tirzepatide | Brand | 14 | $14,297 | |
| Myrbetriq Mirabegron | Brand | 16 | $12,392 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 19 | $11,657 |
The 10 drugs with the highest cost, of 136 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 51 billing codesPaid by Medicare
$9,356
Medicare patients
142
Services billed
3,092
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 35% | |
| Diabetes | 31% | |
| Ischemic heart disease | 25% | |
| COPD | 17% | |
| Atrial fibrillation | 16% | |
| Chronic kidney disease | 15% | |
| Heart failure | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 20 | 1,740 | $104 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 42 | 263 | $69 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 29 | 150 | $10 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Registered Nurse, General Practice in Tennessee
Related records
Registered Nurse, General Practice in Tennessee
Practitioners in the same specialty and state, ranked by reported value.
All Registered Nurse, General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Tennessee
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.